Impetus Digital

MARCH 15, 2024

In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. However, with rapid growth comes growing pains.

Recruitment 78

Recruitment Healthcare Provider Patients Healthcare 78

PM360

JULY 13, 2023

Patients now demand greater access to their health information, desire more communication with their healthcare providers, and seek personalized care tailored to their individual needs. Patients increasingly expect a seamless healthcare experience in which all their health information is integrated and easily accessible.

Healthcare 98

Healthcare Healthcare Consulting Healthcare Provider 98

Clarivate

APRIL 18, 2024

The downsizing is not a total reversal of Walgreens’ aggressive primary-care clinic expansion plan (which in 2021 imagined 1,000 VillageMD clinics by 2027), but rather a reallocation of capital to increase VillageMD’s density in “high-opportunity” markets—i.e., those with high patient volumes.

Retail 52

Retail Healthcare Healthcare Physicians 52

Clarivate

APRIL 24, 2023

After Walgreens upped its ownership stake in the primary-care company VillageMD from 30 to 63 percent and then announced plans to operate 1,000 clinics by 2027, the writing was on the wall: to stay competitive and manage costs in CVS’ newly integrated Aetna plan, CVS could benefit by making a larger bid for primary care of its own.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Pharmaceutical Technology

NOVEMBER 30, 2022

NICE has only allowed healthcare providers to prescribe continuous treatment of the drug for two years. Results from this trial are scheduled to be released in October 2027, and may allow non-diabetic obese patients to have access to Mounjaro. 2021 was a year of continued innovation and change in the Biopharmaceutical industry.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

NICE has only allowed healthcare providers to prescribe continuous treatment of the drug for two years. Results from this trial are scheduled to be released in October 2027, and may allow non-diabetic obese patients to have access to Mounjaro. 2021 was a year of continued innovation and change in the Biopharmaceutical industry.

Medical 98

Medical Manufacturing Insurance Side effects 98